Literature DB >> 32646933

Acute ophthalmoplegia in a patient with anti-GQ1b antibody and chronic facial diplegia.

Fanny Huynh Du1, Alexan Yerevanian2, Matthew Shtrahman3.   

Abstract

A 56-year-old man with a remote history of bilateral recurrent facial palsies presented with a week of ophthalmoplegia with intact deep tendon reflexes and lack of ataxia, cerebrospinal fluid with albuminocytologic dissociation and elevated serum anti-ganglioside Q1b (GQ1b) IgG antibody. We diagnosed the patient with acute ophthalmoplegia without ataxia, a condition under the spectrum of anti-GQ1b antibody syndromes which also includes Miller Fisher syndrome. Given the rarity of recurrent facial palsies and anti-GQ1b antibody syndromes as well as reports associating facial palsies and this syndrome, we suggest that our case may be an unusual presentation of an anti-GQ1b antibody syndrome beginning with recurrent facial palsies several years prior to ophthalmoplegia. Prior studies of human nerves provide insight into the pathophysiology, including ganglioside distribution and cross-reactivities underlying the heterogeneity of anti-GQ1b antibody syndromes. This report may expand the differential diagnosis in patients with recurrent facial palsies and broaden the phenotype of anti-GQ1b syndromes. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cranial nerves; immunology; neuromuscular disease; neuroopthalmology; skin

Mesh:

Substances:

Year:  2020        PMID: 32646933      PMCID: PMC7351293          DOI: 10.1136/bcr-2020-234319

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  25 in total

1.  Optic neuritis in anti-GQ1b positive recurrent Miller Fisher syndrome.

Authors:  J W Chan
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  Miller Fisher Syndrome: A Case Report Highlighting Heterogeneity of Clinical Features and Focused Differential Diagnosis.

Authors:  Ilya V Yepishin; Randall Z Allison; David A Kaminskas; Natalia M Zagorski; Kore K Liow
Journal:  Hawaii J Med Public Health       Date:  2016-07

3.  Intravenous immunoglobulin therapy for Miller Fisher syndrome.

Authors:  Masahiro Mori; Satoshi Kuwabara; Toshio Fukutake; Takamichi Hattori
Journal:  Neurology       Date:  2007-04-03       Impact factor: 9.910

4.  Clinical features and prognosis of Miller Fisher syndrome.

Authors:  M Mori; S Kuwabara; T Fukutake; N Yuki; T Hattori
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

5.  Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.

Authors:  Gianluca Vecchietti; Katrin Kerl; Christa Prins; Gürkan Kaya; Jean-Hilaire Saurat; Lars E French
Journal:  Arch Dermatol       Date:  2006-02

6.  Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome.

Authors:  A Chiba; S Kusunoki; H Obata; R Machinami; I Kanazawa
Journal:  Brain Res       Date:  1997-01-16       Impact factor: 3.252

Review 7.  Bilateral facial nerve palsy associated with Epstein-Barr virus infection with a review of the literature.

Authors:  Kihei Terada; Takahiro Niizuma; Yasuko Kosaka; Miwa Inoue; Satoko Ogita; Naoki Kataoka
Journal:  Scand J Infect Dis       Date:  2004

Review 8.  Anti-GQ1b ganglioside antibody in peripheral nervous system disorders: pathophysiologic role and clinical relevance.

Authors:  Konstantinos Paparounas
Journal:  Arch Neurol       Date:  2004-07

9.  Optic neuritis in a patient with Miller-Fisher syndrome.

Authors:  Praween Lolekha; Kammant Phanthumchinda
Journal:  J Med Assoc Thai       Date:  2008-12

Review 10.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.